SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEARTResearch in context

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEARTResearch in context

Summary: Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce rates of heart failure hospitalisations and cardiovascular death in patients with type 2 diabetes and prior cardiovascular disease. We hypothesised that SGLT2 inhibitors could provide cardiovascular be...

Full description

Bibliographic Details
Main Authors: Hans Christian Rosén, Moman A. Mohammad, Tomas Jernberg, Stefan James, Jonas Oldgren, David Erlinge
Format: Article
Language:English
Published: Elsevier 2024-10-01
Series:The Lancet Regional Health. Europe
Subjects:
Myocardial infarction
Sodium-glucose co-transporter-2 (SGLT2) inhibitors
Type 2 diabetes mellitus
Heart failure
SWEDEHEART
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776224001996

Internet

http://www.sciencedirect.com/science/article/pii/S2666776224001996

Similar Items